Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Collaborations Pharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, yet they are both located within 1 distinct art unit. This indicates that while the technical focus is narrow enough to stay within one unit, the company is facing different examiner perspectives for its current filings.
RICCI, CRAIG D is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. Since there are 2 pending actions and 2 distinct examiners, the workload is evenly divided. This requires practitioners to manage two separate prosecution tracks, each with its own examiner-specific requirements, even though they share the same art unit context. The lack of examiner concentration means that no single individual's preferences will dictate the entire portfolio's outcome.
The concentration in 1 distinct art unit within the Biotechnology & Pharmaceuticals field may offer some consistency in the technical standards applied. However, the presence of 2 distinct examiners means that the company must address two different sets of feedback. Practitioners should tailor their responses to the individual styles of each examiner while ensuring the 2 pending office actions are progressed efficiently within the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18220034 | USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS | HERNANDEZ, JACKSON J | 56d |
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | — | §102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18220034 | USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS | HERNANDEZ, JACKSON J | 1627 | §103 | Non-Final OA | 56d | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial